Key Drivers
- Gross Margin
- Liquidity Buffer
- Leverage Pressure
AIAI Summary
IRTC has shifted from a pure growth story to a prove-it setup, with strong revenue growth, 71% gross margins, and full-year positive free cash flow, but the stock likely stays capped until it consistently converts scale into durable operating cash flow and resolves DOJ/litigation overhangs.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Gross Margin
- •Liquidity Buffer
- •Leverage Pressure
IRTC's core economics remain healthy with a 71% gross margin and strong liquidity, but ongoing losses, high operating expenses, leverage, and a rich valuation mean the stock still depends on future margin and cash-flow improvement.
Price Behavior
Key Price Behavior Insights:
- •Lower highs
- •Support holding
- •Weak momentum
IRTC has been in a clear last month downtrend, down about 9%, but the selloff has slowed near $114, leaving room for a bounce while the broader trend remains bearish.
The decline slowed near $114.00 after a roughly 9% drop
Sentiment & News
Key News Insights:
- •Raised outlook
- •Clinical validation
- •Analyst upside
iRhythm delivered a strong Q1 update with narrower losses, revenue above estimates, and a raised 2026 outlook, while new clinical data and conference activity reinforced the growth story.
The news is bullish for IRTC, suggesting improving execution, stronger demand, and greater confidence in its long-term monitoring platform
Similar Companies in Healthcare
Other companies in the same sector with AI ratings